References
- Andrews P , ThomasH, PohlkeR, SeubertJ. Praziquantel. Med. Res. Rev.3, 147–200 (1983).
- Fenwick A , SavioliL, EngelsD, BergquistNR, ToddMH. Drugs for the control of parasitic diseases: current status and development in schistosomiasis. Trends Parasitol.19, 509–515 (2003).
- World Health Organization . Accelerating work to overcome the global impact of neglected tropical diseases – a roadmap for implementation. World health Organization, Geneva, Switzerland (2012). www.who.int/neglected_diseases
- Uniting to combat neglected tropical diseases. http://unitingtocombatntds.org
- Bühring KU , DiekmannHW, MüllerH, GarbeA, NowakH. Metabolism of praziquantel in man. Eur. J. Drug Metab. Pharm.3, 179–190 (1978).
- Wegner DHG . The profile of the trematodicidal compound praziquantel. Arzneimittelforschung34, 1132–1136 (1984).
- Black CL , SteinauerML, MwinziPN, SecorWE, KaranjaDM, ColleyDG. Impact of intense, longitudinal retreatment with praziquantel on cure rates of schistosomiasis mansoni in a cohort of occupationally exposed adults in western Kenya. Trop. Med. Int. Health.14, 450–457 (2009).
- Woelfle M , OlliaroP, ToddMH. Open science is a research accelerator. Nat. Chem.3, 745–748 (2011).
- Woelfle M , SeerdenJP, de GooijerJ, PouwerK, OlliaroP, ToddMH. Resolution of praziquantel. PLoS Negl. Trop. Dis.5, e1260 (2011).